AMPK–SQSTM1/p62 Feedback Enhances Antioxidant Defense in Metabolic Stress

Study Background and Research Question

Metabolic and oxidative stresses are hallmarks of the tumor microenvironment, particularly in cancers such as non-small cell lung cancer (NSCLC) with frequent co-occurring mutations in STK11/LKB1 and KEAP1. These stresses result from nutrient deprivation and reactive oxygen species (ROS) accumulation, challenging tumor cell survival and growth. AMP-activated protein kinase (AMPK), a master regulator of cellular metabolism, is activated during energy deprivation to restore ATP and NADPH levels—critical for both bioenergetic balance and antioxidant defense. Simultaneously, the KEAP1-NFE2L2/NRF2 pathway is known to mediate cellular adaptation to oxidative stress. However, the regulatory crosstalk between these two pathways, especially during metabolic adaptation in cancer, remains poorly defined. This reference study (AUTOPHAGY 2024) aims to elucidate how metabolic stress orchestrates a feedback mechanism that integrates AMPK and SQSTM1/p62 with dual activation of AMPK and NFE2L2/NRF2.

Key Innovation from the Reference Study

The principal innovation lies in the discovery of a double-positive feedback loop between AMPK and SQSTM1/p62. This mutual reinforcement enables simultaneous activation of AMPK and the antioxidant transcription factor NFE2L2/NRF2 under metabolic stress. The study demonstrates that metabolic stress upregulates the expression and phosphorylation of SQSTM1/p62, which in turn is essential for activating both AMPK and NFE2L2/NRF2. This dual activation synergistically enhances antioxidant defense, thereby supporting tumor cell survival and proliferation in hostile microenvironments. Importantly, the research uncovers the mechanistic basis for this feedback, highlighting the pivotal roles of lysosomal function, ROS signaling, and phosphorylation events.

Methods and Experimental Design Insights

The investigators employed a combination of biochemical, genetic, and cell biological approaches in both cancer cell lines and mouse embryonic fibroblasts (MEFs). Key experimental methods included:

• Induction of metabolic stress via glucose deprivation and pharmacological agents.
• Manipulation of gene expression using RNA interference and overexpression constructs for AMPK, SQSTM1/p62, and related pathway components.
• Phosphorylation and expression analyses by immunoblotting and immunoprecipitation, specifically examining SQSTM1/p62 modifications at key serine residues (S24, S226).
• Assessment of lysosomal pH and Ca²⁺ signaling using live-cell imaging and specific dyes.
• Functional assays for antioxidant response and tumor growth in vitro and in xenograft models.
• Use of pharmacological inhibitors and activators, including those targeting calcineurin (such as FK506), to dissect signaling dependencies.

This multifaceted approach enabled the authors to map the molecular sequence of events and establish causality within the feedback loop framework.

Core Findings and Why They Matter

The study demonstrates that metabolic stress leads to increased expression and phosphorylation of SQSTM1/p62, which is necessary for activating both AMPK and NFE2L2/NRF2. Mechanistically, this is achieved through two major processes:

• Macroautophagic Degradation of KEAP1: SQSTM1/p62 facilitates the autophagic clearance of KEAP1, thereby releasing NFE2L2/NRF2 to drive antioxidant gene expression.
• Facilitation of AXIN-STK11-AMPK Complex Formation: On the lysosomal membrane, SQSTM1/p62 promotes assembly of the signaling complex necessary for AMPK activation.

Conversely, AMPK activity is required for metabolic stress-induced SQSTM1/p62 expression and phosphorylation, establishing a double-positive feedback loop. The study further elucidates upstream regulators: PPP2/PP2A-dependent dephosphorylation of TFEB/TFE3 (promoting SQSTM1 transcription) is triggered by lysosomal deacidification under low glucose, while ROS-activated MAP3K7/TAK1 and lysosomal Ca²⁺ release increase SQSTM1 phosphorylation. Phosphorylation at S24 and S226 on SQSTM1 is shown to be critical for the dual activation process. The feedback loop is abrogated by lactic acid-induced proton influx, linking metabolic byproducts to pathway regulation.

Collectively, these findings provide a mechanistic explanation for the frequent co-occurrence of STK11 and KEAP1 mutations in NSCLC, as dual pathway activation offers a survival advantage under metabolic stress. The study also identifies potential therapeutic targets for disrupting this adaptive mechanism in cancer.

Comparison with Existing Internal Articles

Previous internal resources, such as the article "AMPK–SQSTM1 Feedback Drives Antioxidant Defense in Metabolic Stress", provide an accessible summary of the feedback loop and its implications for tumor adaptation. However, the current reference study adds critical mechanistic depth, detailing the roles of lysosomal pH, Ca²⁺ signaling, and specific phosphorylation sites on SQSTM1. Additionally, the workflow-focused articles on Tacrolimus (FK506) and immune response suppression tools focus on T-cell activation and cytokine pathway modulation. While these guides do not directly address the AMPK–SQSTM1 feedback, they contextualize the use of calcineurin inhibitors (such as FK506) for dissecting phosphatase-dependent pathways, which is relevant for experimental manipulation of related signaling nodes.

Limitations and Transferability

Despite the comprehensive mechanistic mapping, several limitations warrant consideration. First, the primary data are derived from cell lines and mouse models, which may not fully recapitulate the complexity of human tumors. Second, while the double-positive feedback loop is robustly demonstrated under defined metabolic stress conditions, its operation in diverse tumor microenvironments and in the presence of additional oncogenic mutations requires further validation. Third, the therapeutic implications for targeting these pathways remain preliminary, as the study does not directly test pharmacological interventions that disrupt the feedback loop in vivo. Finally, while the findings offer a compelling rationale for the frequent co-occurrence of STK11 and KEAP1 mutations, causality in clinical samples remains to be established.

Protocol Parameters

• Metabolic stress induction: Glucose deprivation or pharmacological inhibition of glycolysis; adjust conditions to match cell line metabolic profile.
• SQSTM1/p62 modulation: Use RNAi or CRISPR-Cas9 for gene knockdown; overexpress wild-type or phosphorylation-deficient mutants (S24A, S226A) to assess functional impact.
• AMPK pathway activity: Monitor phosphorylation status at AMPKα T172; employ activators or inhibitors as needed for mechanistic studies.
• Autophagic flux assessment: Employ LC3-II turnover and KEAP1 degradation as readouts; use bafilomycin A1 or concanamycin A to block lysosomal degradation if necessary.
• Calcineurin pathway manipulation: Apply Tacrolimus (FK506) at 2–4 μM in cell culture to inhibit calcineurin and assess downstream effects on phosphatase-dependent signaling (product information).
• Lysosomal pH/Ca²⁺ monitoring: Use appropriate fluorescent dyes and live-cell imaging; titrate lactic acid or protonophores to modulate lysosomal acidity.

Research Support Resources

Researchers seeking to probe calcineurin-dependent signaling, T-cell activation, or cytokine pathway modulation in the context of metabolic or oxidative stress may find Tacrolimus (FK506) (SKU B2143) from APExBIO a suitable tool compound. Its nanomolar potency and selectivity as a calcineurin inhibitor facilitate dissection of phosphatase-driven regulatory mechanisms in immune response and stress adaptation models. For detailed protocol strategies and troubleshooting, internal literature such as "Tacrolimus (FK506): Applied Workflows for Immune Modulation" provides additional practical guidance for transplantation immunology research and autoimmune disease models.